StockMarketWire.com - Rare-disease focused biopharmaceutical company Mereo Biopharma Group announced that Oncomed stockholders had approved December's merger agreement for Oncomed to become a subsidiary of Mereo.

The merger was now expected to occur and become fully effective by the close of business in New York on 23 April 2019.

In connection with the completion of the merger, it was expected that Mereo would issue 24,783,320 new ordinary shares (representing approximately 25.8% of the enlarged issued share capital of Mereo) to Citibank, N.A., London Branch, as custodian, and would instruct Citibank, N.A., as depositary, to deliver 4,956,664 American Depositary Shares to former stockholders of OncoMed.

Admission to trading of the new ordinary shares on AIM and of the American Depositary Receipts on the Nasdaq Global Market was expected to take place on 24 April 2019.


At 9:44am: [LON:MPH] Mereo Biopharma Group Ltd share price was 0p at 165p



Story provided by StockMarketWire.com